Palliative embolization for metastases of the spine: pain relief is temporary
A study has assessed palliative selective and superselective arterial embolization with N-butyl-cyanoacrylate ( n-BCA ) for cancer patients with spinal metastases. Researchers studied the files of ...
Effect of bisphosphonates, Denosumab, and radioisotopes on bone pain and quality of life in non-small cell lung cancer patients and bone metastases
Bone metastases are common in patients with non-small cell lung cancer ( NSCLC ), often causing pain and a decrease in quality of life ( QoL ). The effect of bone-targeted agents is evaluated by reduc ...
Previously-treated patients with non-small cell lung cancer with PD-L1 expression: Pembrolizumab improves survival compared to Docetaxel, an chemotherapy drug
Results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in p ...
Stage III or IV larynx or hypopharynx invasive squamous cell carcinoma: induction chemotherapy with Cisplatin, 5-Fluorouracil, plus or minus Docetaxel for larynx preservation
The purpose of GORTEC 2000-01 was to compare the long-term efficacy and safety of induction chemotherapy with Cisplatin ( P ) and 5-Fluorouracil ( F ) with or without Docetaxel ( T ) for larynx preser ...
Preoperative chemotherapy plus Trastuzumab, Lapatinib or both in HER2-positive operable breast cancer: safety report
Researchers conducted a phase IIb randomized trial of preoperative chemotherapy ( CT ) plus Trastuzumab ( T ), Lapatinib ( L ), or the combination of Trastuzumab plus Lapatinib in HER2+ operable breas ...
Atezolizumab, a cancer immunotherapy, shrank tumors in patients with locally advanced or metastatic non-small cell lung cancer
In the large pivotal phase II study, BIRCH, the investigational cancer immunotherapy Atezolizumab ( MPDL3280A; anti-PD-L1 ) met its primary endpoint and shrank tumors ( objective response rate; ORR ) ...
Patients with previously treated non-squamous non-small cell lung cancer: Nivolumab has demonstrated superior overall survival versus Docetaxel
Longer term ( 18 month ) survival data from CheckMate -057, an open-label, randomized phase 3 study evaluating Nivolumab [ Opdivo ] ( n=292 ) versus Docetaxel [ Taxotere ] ( n=290 ) in previously trea ...
Cancer treatment in elderly patients: evidence and clinical research
In 2020 the percentage of patients with a diagnosis of cancer in people with more than 65 years will exceed 70% and 28% in ethnic minorities. The treatment of cancer in these populations is challengin ...
Previously treated advanced renal cell carcinoma: Nivolumab achieved a median overall survival of 25 months, greater than 5 month improvement over Everolimus
Results from CheckMate -025, a phase 3 study comparing Nivolumab ( Opdivo ) to Everolimus ( Afinitor ) in advanced renal cell carcinoma ( RCC ) after prior anti-angiogenic treatment, showed a signific ...
Cancer immunotherapy: Atezolizumab has demonstrated benefits in patients with advanced non-small cell lung cancer expressing PD-L1
Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with advanced non-small cell lung cancer ( NSCLC ) we ...
Investigational immunotherapy for advanced bladder cancer: results show PD-L1 expression correlated with response to Atezolizumab
Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...
Treatment of advanced non-small cell lung cancer with Pembrolizumab, a monoclonal antibody that blocks the interaction between PD-1 and its ligands
New data from KEYNOTE-001, a phase 1b study evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in naïve and previously-treated patients with advanced non-small cell lung cancer ( NSCLC ) wer ...
ASCO clinical practice guideline: systemic therapy for stage IV non–small-cell lung cancer
A Committee of the American Society of Clinical Oncology NSCLC Expert Panel carried out a systematic review of randomized controlled trials from January 2007 to February 2014 to provide evidence-base ...
Non-small cell lung cancer: low EGFR/MET ratio is associated with resistance to EGFR inhibitors
Although activating mutations in the epidermal growth factor receptor ( EGFR ) gene are predictive markers for response to EGFR inhibitors, 30-40% of EGFR-mutant non-small cell lung cancer ( NSCLC ) p ...
MARIANNE trial: T-DM1 does not improve progression-free survival compared with Trastuzumab plus a taxane in patients with locally advanced or metastatic HER2-positive breast cancer
T-DM1 ( Trastuzumab emtansine; Kadcyla ) treatment resulted in non-inferior, but not-superior, progression-free survival ( PFS ) compared with Trastuzumab plus a taxane ( HT ) in patients with locally ...
